中文名 | JANEX-1 |
英文名 | JANEX-1 |
别名 | 3-氰基-5-[[3 化合物WHI-P131 JAK3抑制剂(JANEX-1) 4-(4-羟基苯胺)-6,7-二甲氧基喹唑啉 4-((6,7-二甲氧基喹唑啉-4-基)氨基)苯酚 4-(4'-羟基苯基)氨基-6,7-二甲氧基喹唑啉 5-二乙基-1-(2-羟基乙基)-1H-吡唑-4-基]氧基]苯腈 |
英文别名 | Janex 1 JANEX-1 WHI-P131 JAK3 INHIBITOR I WHI-P131(Janex 1) A JAK3 inhibitorWHI-P131 4-(6,7-dimethoxyquinazolin-4-ylamino)phenol 4-(4'-HYDROXYPHENYL)AMINO-6,7-DIMETHOXYQUINAZOLINE |
CAS | 202475-60-3 |
化学式 | C16H15N3O3 |
分子量 | 297.31 |
密度 | 1.336±0.06 g/cm3(Predicted) |
沸点 | 468.1±40.0 °C(Predicted) |
溶解度 | DMSO: 18mg/ml,可溶 |
酸度系数 | 10.06±0.26(Predicted) |
存储条件 | Keep in dark place,Inert atmosphere,2-8°C |
稳定性 | 从提供的购买之日起稳定2年。防潮。DMSO中的溶液可以在-20 °C下储存长达2个月。 |
外观 | 固体 |
颜色 | yellow |
体外研究 | JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC 50 of 78 μM), does not inhibit JAK1 and JAK2, the ZAP/SYK family tyrosine kinase SYK, the TEC family tyrosine kinase BTK, the SRC family tyrosine kinase LYN, or the receptor family tyrosine kinase insulin receptor kinase, even at concentrations as high as 350 μM. JANEX-1 induces apoptosis in JAK3-expressing human leukemia cell lines NALM-6 and LC1;19 but not in melanoma (M24-MET) or squamous carcinoma (SQ20B) cells. WHI-P131 inhibits the clonogenic growth of JAK3-positive leukemia cell lines DAUDI, RAMOS, LC1;19, NALM-6, MOLT-3, and HL-60 (but not JAK3-negative BT-20 breast cancer, M24-MET melanoma, or SQ20B squamous carcinoma cell lines) in a concentration-dependent fashion. WHI-P131 inhibits clonogenic growth in a concentration-dependent fashion with EC 50 s of 24.4 μM for NALM-6 cells and 18.8 μM for DAUDI cells. At 100 μM, WHI-P131 inhibits the in vitro colony formation by these leukemia cell lines by >99%. In contrast, JANEX-1 does not inhibit the clonogenic growth of JAK3-negative M24-MET melanoma or SQ20B squamous carcinoma cell lines. |
体内研究 | JANEX-1 is administered at doses ranging from 5 to 100 mg/kg. Evaluation of CPK activity revealed a dose-response curve with an effective dose 50 (ED 50 ) value of 7.44 mg/kg. Mice receiving JANEX-1 displayed significantly reduced CPK and LDH levels. In addition, the infarct size of JANEX-1-treated mice (30.16±2.79%) is significantly decreased when compared with I/R-operated mice (65.64±3.76%). JANEX-1 (WHI-P131) is absorbed rapidly, and the time to reach the maximum plasma JANEX-1 concentration (t max ) is 24.7±1.7 min. JANEX-1 is rapidly eliminated with an elimination half-life of 45.6±5.5 min. Although the predicted maximum plasma JANEX-1 concentration is 10.5 ± 0.8 μM, which is only half of the C max following i.v. administration of the same bolus dose, the i.p. bioavailability is 94.6% and the systemic exposure levels (i.e., AUC) are very similar to those observed after i.v. injection (17.1±2.2 μM•h versus 18.1±1.2 μM•h). |
危险品标志 | Xi - 刺激性物品 |
风险术语 | 36/37/38 - 刺激眼睛、呼吸系统和皮肤。 |
安全术语 | S26 - 不慎与眼睛接触后,请立即用大量清水冲洗并征求医生意见。 S36 - 穿戴适当的防护服。 |
WGK Germany | 3 |
上游原料 | 6,7-二甲氧基喹唑啉-4-酮 4,5-二甲氧基-2-硝基苯甲酰胺 4-氯-6,7-二甲氧基喹唑啉 2-氨基-4,5-二甲氧基苯甲酰胺 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.363 ml | 16.817 ml | 33.635 ml |
5 mM | 0.673 ml | 3.363 ml | 6.727 ml |
10 mM | 0.336 ml | 1.682 ml | 3.363 ml |
5 mM | 0.067 ml | 0.336 ml | 0.673 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!